Boston Scientific will pay $500m upfront and up to $100m in milestone payments to acquire Augmenix, providing exits to Varian Medical Systems and Ascension Health.
Augmenix, a US-based radiation oncology technology producer backed by corporates Varian Medical Systems and Ascension Health, was acquired by medical devices maker Boston Scientifc on Thursday.
Boston Scientific will pay $500m in upfront cash and up to an additional $100m if Augmenix reaches sales-based milestones. The acquisition is expected to close in the fourth quarter of 2018 once it has cleared customary closing conditions.
Founded in 2008, Augmenix has developed an absorbable hydrogel, called SpaceOar System, that is injected prior…
